LONDON CANCER COLORECTAL CANCER PATHWAY BOARD

Transcription

1 LONDON CANCER COLORECTAL CANCER PATHWAY BOARD Date: Tuesday, 24 th July 2012, 17:30-19:00 Venue: Boardroom, 3 rd Floor, UCLP, 170 Tottenham Court Road, London W1T 7HA Chair: Mr Michael Machesney ACTION LOG: Action Owner Date Agreed Status Members to send Tim Burdsey any achievements and challenges for the last year to be reflected in Peer Review documentation. Helen Pardoe, Ed Seward, Jacquie Peck and Michael Machesney to report back at the next Pathway Board meeting on their progress in establishing their sub-groups and generating initial ideas. All 24/07/2012 Completed before 04/09/2012 HP, ES, JP and MM 24/07/2012 Completed before September meeting 1. Welcome and Introductions MM welcomed the board and shared apologies that had been received (see Appendix 1). 2. London Cancer update TB presented a document (attached with these minutes) that outlined the current governance structure of London Cancer. TB reported that all Pathway Boards have now met at least once and that the next step is to establish cross-cutting Expert Reference Groups. The London Cancer board is meeting monthly and is currently working monthly with Pathway Directors to review and refine the strategic objectives for each Pathway Board. 3. Early detection of colorectal cancer Presentation from Frances Haste (Original Agenda Item 6) Dr Frances Haste, Consultant in Public Health from NELCN, gave a presentation (enclosed with these minutes) to the Pathway Board on early diagnosis and colorectal cancer in the London Cancer ICS area. The presentation highlighted: a. The relatively poor survival of patients that present via emergency routes. b. Reasons for poor survival, which included late presentation, delays in primary care and delays in secondary care. c. Challenges for the future, including improving the quality of staging data, developing protocols in primary and acute care, clear feedback to GPs and targeting areas of poor survival. 1

2 4. Agreeing our objectives as a Pathway Board, developing our workplan and forming delivery sub-groups MM shared with the group details of the four working sub-groups that will lead on the work against the objectives agreed at the last Pathway Board meeting. MM discussed the importance of increasing participation in screening, improving diagnostic pathway and developing improved follow up of patients. Develop a London Cancer operational policy and identify risks preventing implementation of the standards Miss Helen Pardoe Provide one clinical guideline for London cancer merging the NCL and NELCN guidelines in the light of the new NICE guidance and commissioning documents. Provide a forum for lead clinicians (or their representative ) from all colorectal MDTs in London Cancer to meet at least 4 times per year. In addition to producing and approving the unified clinical guidelines they will be tasked to ask the MDT representatives to inform the working group of any concerns they have that prevent their MDT from delivering the standards in the clinical guidance. Al concerns will be reported to the Pathway Board. MM identified another working group that will work on screening and increasing patient participation. Increase participation in bowel screening Mr Michael Machesney Focus on increasing participation in bowel screening MM outlined that he had asked Dr Ed Seward to lead a working group to improve the diagnostic pathway from GP referral. MM discussed the conventional diagnostic pathway based on presumed diagnosis in primary care (document circulated with these minutes) and compared it to the proposed use of straight to test including increased access to colonoscopy. Members of the group agreed that there is a need to increase the access of patients to diagnostic services to provide them with a definitive diagnosis of new onset bowel symptoms. Developing the diagnostic service Dr Ed Seward A working group will be formed to share ideas and identify sites for pilots that could be commissioned for HP identified barriers to the GP triaging diagnostics such as uncontactable patients, issues with language, and patients who choose to delay the test. HP also emphasised the need to ensure 2

3 patients are treated locally to ensure easier follow-up. PM added that Barnet and Chase Farm had attempted to establish a one stop service for colorectal cancer; however, this has proven difficult given the impact on providing extra endoscopy services. JP will lead a working group focusing on patient follow-up. MM explained that this group would be improving follow up by providing a uniform system for London Cancer where follow up investigations were booked independently of follow up outpatient appointments. JI explained that she would be keen to discuss the Board s view on what to focus on in follow-up as it was important to maintain close relationships with clinical boards. Improving follow-up Miss Jacquie Peck Produce a London Cancer standard follow up pathway for colorectal cancer patients working with the group led by HP Develop a follow up model building on the Broomfield model Embed current Living with and beyond cancer psychosocial interventions in follow-up protocols Improve patient experience 5. Research and audit Update on trials performance SS discussed how there was no universal database of phase 1 trials to be recorded. MM stated that Professor Nick Lemoine, Chair of the Research Implementation Board, had been appointed. 6. Peer Review TB informed the group that the self-assessment and internal validation for the colorectal cancer pathway will take place on 4 th September TB encouraged members to share with him details of achievements and challenges over the last year for inclusion in the colorectal Peer Review documentation. ACTION: Members to send Tim Burdsey any achievements and challenges for the last year to be reflected in Peer Review documentation 7. Presentation: Early detection of colorectal cancer (Original Agenda Item 6) Jill Ireland presented to the board on Improvement Projects in NCL/WECCN, NELCN. She described work on GP education, system related issues and public awareness. JE outlined specific targeted community centred events in an awareness campaign (April-June 2011) as well as social marketing campaigns, and one case of deeper community work with Tottenham Hotspur and Arsenal to deliver community champions and leaders to discuss signs and symptoms of colorectal cancer. The major issue centred on the lack of long term funding for projects and future steps including establishing funding to develop programmes from Autumn March

4 8. AOB HM informed the group that colleagues within Whittington Health had produced a research report for their programme of work to define best practice pathway for colorectal cancer. MM added that this document will be a useful input into the Pathway Board s discussions in the future. 9. Time and date of future meetings It was agreed to rotate meeting times between the times of 8:00 a.m-9:30 a.m. and 5:30p.m.- 7:00 p.m. The next meeting will take place on Monday 24 th September from 8:00-9:30 a.m. 4

5 Appendix 1 Attendees Name Arthur Anderson Clare Stephens Farrukh Rashid Hannah Burleton Hasan Mukhtar Helen Pardoe Jacquie Peck Jessica Sheringham Kim Jaggs Lee Dvorkin Michael Machesney Olutunde Lalude Pauline McCulloch Pawan Mathur Sarah Slater Tim Burdsey Lucia Grun Sue Williams Patricia Jupp Frances Haste Jill Ireland Apologies Name Caroline Moren Ed Seward Hitesh Patel John Bridgewater Kim Ainsworth Marc Winslet Sherif Raouf Organisation Patient Representative NHS Barnet NHS Leyton London Cancer WH HUH UCLH UCL BCFH NMUH PAH HUH BCFH London Cancer Camden CCG NMUH Patient Representative NELCN NHS North Central London Organisation NELCN UCL UCL/RFH R 5